Treating metastatic cancer with nanotechnology

Schroeder, Avi; Heller, Daniel A.; Winslow, Monte M.; Dahlman, James E.; Pratt, G. W.; Langer, Robert; Jacks, Tyler; Anderson, Daniel G.

doi:10.1038/nrc3180

Cited by 1,079 publications

(849 citation statements)

References 214 publications

Supporting

Mentioning

835

Contrasting

Unclassified

Order By: Relevance

“…[ 12,13 ] The unique architecture of AFt provides two interfaces: the outer surface of AFt can be modifi ed chemically or genetically with functional motifs [ 14 ] and the internal cavity can be used to encapsulate pharmaceutical agents such as anticancer drugs, magnetic resonance imaging (MRI), and fl uorescent imaging agents. [ 6,9,15,16 ] Recently, selective targeting and cargo delivery with heavy chain apoferritin (H-AFt) was demonstrated both in vitro [ 17 ] and in vivo.…”

mentioning

confidence: 99%

An Apoferritin‐based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

Kuruppu

Zhang

Collins

et al. 2015

Adv Healthcare Materials

View full text Add to dashboard Cite

mentioning

confidence: 99%

An Apoferritin‐based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

Kuruppu

Zhang

Collins

et al. 2015

Adv Healthcare Materials

View full text Add to dashboard Cite

“…The development of enhanced transport systems has revolutionized the approach to improving chemotherapy, and the field of nanotechnology is helping to pave the way [13][14][15]. Through the utilization of various nanoformulations, many of the issues associated with the use of free drugs have been addressed via tunable release of therapeutics, enhanced pharmacokinetic and pharmacodynamic profiles, modifications for superior targeted delivery, and ease of incorporation of multiple agents with differing solubility profiles [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Kemp

Shim

Heo

et al. 2016

Advanced Drug Delivery Reviews

437

258

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oThe dynamic and versatile nature of diseases such as cancer has been a pivotal challenge for developing efficient and safe therapies. Cancer treatments using a single therapeutic agent often result in limited clinical outcomes due to tumor heterogeneity and drug resistance. Combination therapies using multiple therapeutic modalities can synergistically elevate anti-cancer activity while lowering doses of each agent, hence, reducing side effects. Co-administration of multiple therapeutic agents requires a delivery platform that can normalize pharmacokinetics and pharmacodynamics of the agents, prolong circulation, selectively accumulate, specifically bind to the target, and enable controlled release in target site. Nanomaterials, such as polymeric nanoparticles, gold nanoparticles/cages/shells, and carbon nanomaterials, have the desired properties, and they can mediate therapeutic effects different from those generated by small molecule drugs (e.g., gene therapy, photothermal therapy, photodynamic therapy, and radiotherapy). This review aims to provide an overview of developing multi-modal therapies using nanomaterials ("combo" nanomedicine) along with the rationale, up-to-date progress, further considerations, and the crucial roles of interdisciplinary approaches.

show abstract

“…nanoparticles (NPs)) and devices [2] with a wide-range of applications, especially in imaging, diagnostics, and therapy, contributing to the early detection and treatment of cancer and metastasis [3,4]. NPs are within the same size domain as many biomolecules, including enzymes, antibodies, and protein receptors.…”

Section: Introductionmentioning

confidence: 99%

Gold nanoprisms as a hybrid in vivo cancer theranostic platform for in situ photoacoustic imaging, angiography, and localized hyperthermia

et al. 2016

View full text Add to dashboard Cite

The development of high-resolution nanosized photoacoustic contrast agents is an exciting yet challenging technological advance. Herein, antibody (breast cancer-associated antigen 1 (Brcaa1) monoclonal antibody)-and peptide (RGD)-functionalized gold nanoprisms (AuNprs) were used as a combinatorial methodology for in situ photoacoustic imaging, angiography, and localized hyperthermia using orthotopic and subcutaneous murine gastric carcinoma models. RGD-conjugated PEGylated AuNprs are available for tumor angiography, and Brcaa1 monoclonal antibody-conjugated PEGylated AuNprs are used for targeting and for in situ imaging of gastric carcinoma in orthotopic tumor models. In situ photoacoustic imaging allowed for anatomical and functional imaging at the tumor site. In vivo tumor angiography imaging showed enhancement of the photoacoustic signal in a time-dependent manner. Furthermore, photoacoustic imaging demonstrated that tumor vessels were clearly damaged after localized hyperthermia. This is the first proof-of-concept using two AuNprs probes as highly sensitive contrasts and therapeutic agents for in situ tumor detection and inhibition. These smart antibody/peptide AuNprs can be used as an efficient nanotheranostic platform for in vivo tumor detection with high sensitivity, as well as for tumor targeting therapy, which, with a single-dose injection, results in tumor size reduction and increases mice survival after localized hyperthermia treatment.

show abstract

Treating metastatic cancer with nanotechnology

Cited by 1,079 publications

References 214 publications

An Apoferritin‐based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

An Apoferritin‐based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Gold nanoprisms as a hybrid in vivo cancer theranostic platform for in situ photoacoustic imaging, angiography, and localized hyperthermia

Contact Info

Product

Resources

About